Product How it works Pricing Blog FAQ About Contact
Amphastar Pharmaceuticals

Amphastar Pharmaceuticals (NASDAQ: AMPH) revenue

Amphastar Pharmaceuticals reported revenue of $719.9m for fiscal 2025, 1.7% less than in fiscal 2024 ($732.0m). Since fiscal 2016 its revenue has grown by 182.1%, an average growth of 12.2% a year.

Amphastar Pharmaceuticals's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2017, −5.9%.

Revenue, in millions of US dollars255.22016240.22017294.72018322.42019349.82020437.82021499.02022644.42023732.02024719.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$719.9m−1.7%$140.4m19.5%
2024$732.0m+13.6%$205.4m28.1%
2023$644.4m+29.1%$197.0m30.6%
2022$499.0m+14.0%$107.5m21.5%
2021$437.8m+25.1%$69.9m16.0%
2020$349.8m+8.5%$11.0m3.1%
2019$322.4m+9.4%−$0.0m−0.0%
2018$294.7m+22.7%−$8.6m−2.9%
2017$240.2m−5.9%−$1.3m−0.5%
2016$255.2m—$15.4m6.0%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Amphastar Pharmaceuticals revenue compared with its sector

By revenue for its latest fiscal year, Amphastar Pharmaceuticals ranks 176th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Amphastar Pharmaceuticals, −1.7%.

RankCompanyRevenueRevenue growth
174thNeoGenomics$727.3m10.1%
175thPacira Biosciences$726.4m3.6%
176thAmphastar Pharmaceuticals$719.9m−1.7%
177thKiniksa Pharmaceuticals International$677.6m60.1%
178thUltragenyx Pharmaceutical$673.0m20.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Amphastar Pharmaceuticals

How much revenue did Amphastar Pharmaceuticals make in fiscal 2025?
Amphastar Pharmaceuticals reported revenue of $719.9m for fiscal 2025, compared with $732.0m in fiscal 2024.
How much has the revenue of Amphastar Pharmaceuticals grown?
Between fiscal 2016 and fiscal 2025 it went from $255.2m to $719.9m: 182.1% more, an average growth of 12.2% a year.
What was the best year for revenue at Amphastar Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2024, with $732.0m.
Where does Amphastar Pharmaceuticals rank in its sector by revenue?
It ranks 176th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Amphastar Pharmaceuticals come from?
From the annual report (Form 10-K) that Amphastar Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Amphastar Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Amphastar Pharmaceuticals: the Amphastar Pharmaceuticals page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.